Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.

Hack CC, Fasching PA, Fehm T, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Wuerstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesslet T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauss T, Thomssen C, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Brucker SY, Wallwiener D, Kümmel S, Beckmann MW, Paepke D.

Integr Cancer Ther. 2016 Sep 14. pii: 1534735416668575. [Epub ahead of print]

PMID:
27627986
2.

Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline.

Almstedt K, Fasching PA, Scharl A, Rauh C, Rack B, Hein A, Hack CC, Bayer CM, Jud SM, Schrauder MG, Beckmann MW, Lux MP.

Anticancer Res. 2016 Jan;36(1):419-25.

PMID:
26722076
3.

Comparison of Sonography versus Digital Breast Tomosynthesis to Locate Intramammary Marker Clips.

Schulz-Wendtland R, Dankerl P, Dilbat G, Bani M, Fasching PA, Heusinger K, Lux MP, Loehberg CR, Jud SM, Rauh C, Bayer CM, Beckmann MW, Wachter DL, Uder M, Meier-Meitinger M, Brehm B.

Geburtshilfe Frauenheilkd. 2015 Jan;75(1):72-76.

4.

Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study.

Fasching PA, Fehm T, Kellner S, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Würstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesslet T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauß T, Thomssen C, Kümmel S, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Wallwiener D, Grischke EM, Beckmann MW, Brucker SY.

Geburtshilfe Frauenheilkd. 2014 Dec;74(12):1137-1143.

5.

Full Field Digital Mammography (FFDM) versus CMOS Technology, Specimen Radiography System (SRS) and Tomosynthesis (DBT) - Which System Can Optimise Surgical Therapy?

Schulz-Wendtland R, Dilbat G, Bani M, Fasching PA, Heusinger K, Lux MP, Loehberg CR, Brehm B, Hammon M, Saake M, Dankerl P, Jud SM, Rauh C, Bayer CM, Beckmann MW, Uder M, Meier-Meitinger M.

Geburtshilfe Frauenheilkd. 2013 May;73(5):422-427.

6.

Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis.

Fasching PA, Ekici AB, Wachter DL, Hein A, Bayer CM, Häberle L, Loehberg CR, Schneider M, Jud SM, Heusinger K, Rübner M, Rauh C, Bani MR, Lux MP, Schulz-Wendtland R, Hartmann A, Beckmann MW.

Geburtshilfe Frauenheilkd. 2013 Dec;73(12):1228-1235.

7.

Evaluation of Newly Adapted Clip Marker System in Ultrasound-Guided Core Needle Biopsy for Suspicion of Breast Cancer.

Schulz-Wendtland R, Dankerl P, Dilbat G, Bani M, Fasching PA, Heusinger K, Lux MP, Loehberg CR, Jud SM, Rauh C, Bayer CM, Beckmann MW, Uder M, Meier-Meitinger M, Brehm B.

Geburtshilfe Frauenheilkd. 2013 Nov;73(11):1135-1138.

8.

Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients.

Hein A, Bayer CM, Schrauder MG, Häberle L, Heusinger K, Strick R, Ruebner M, Lux MP, Renner SP, Schulz-Wendtland R, Ekici AB, Hartmann A, Beckmann MW, Fasching PA.

Biomed Res Int. 2014;2014:842452. doi: 10.1155/2014/842452.

9.

Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma.

Wachter DL, Hartmann A, Beckmann MW, Fasching PA, Hein A, Bayer CM, Agaimy A.

Biomed Res Int. 2014;2014:408459. doi: 10.1155/2014/408459.

10.

Assessment of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective CGATE study.

Bayer CM, Bani MR, Schneider M, Dammer U, Raabe E, Haeberle L, Faschingbauer F, Schneeberger S, Renner SP, Fischer D, Schulz-Wendtland R, Fasching PA, Beckmann MW, Jud SM.

Eur J Cancer Prev. 2014 May;23(3):151-7. doi: 10.1097/CEJ.0b013e3283651ccb.

PMID:
24100511
11.

Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors.

Lux MP, Bayer CM, Loehberg CR, Fasching PA, Schrauder MG, Bani MR, Häberle L, Engel A, Heusinger K, Tänzer T, Radosavac D, Scharl A, Bauerfeind I, Gesslein J, Schulte H, Overbeck-Schulte B, Beckmann MW, Hein A.

Breast Cancer Res Treat. 2013 Jun;139(2):429-40. doi: 10.1007/s10549-013-2557-3.

PMID:
23670130
12.

Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis.

Loehberg CR, Almstedt K, Jud SM, Haeberle L, Fasching PA, Hack CC, Lux MP, Thiel FC, Schrauder MG, Brunner M, Bayer CM, Hein A, Heusinger K, Heimrich J, Bani MR, Renner SP, Hartmann A, Beckmann MW, Wachter DL.

Breast Cancer Res Treat. 2013 Apr;138(3):899-908. doi: 10.1007/s10549-013-2460-y.

PMID:
23479421
13.

Factors influencing breast changes after pregnancy.

Rauh C, Faschingbauer F, Haeberle L, Jud SM, Heusinger K, Fasching PA, Goecke TW, Rajakaruna N, Voigt F, Bani MR, Lux MP, Renner SP, Loehberg CR, Hartmann A, Schulz-Wendtland R, Beckmann MW, Bayer CM.

Eur J Cancer Prev. 2013 May;22(3):259-61. doi: 10.1097/CEJ.0b013e328359cb81.

PMID:
23022745
14.

Hormone replacement therapy and prognosis in ovarian cancer patients.

Hein A, Thiel FC, Bayer CM, Fasching PA, Häberle L, Lux MP, Renner SP, Jud SM, Schrauder MG, Müller A, Wachter D, Strehl J, Hartmann A, Beckmann MW, Rauh C.

Eur J Cancer Prev. 2013 Jan;22(1):52-8. doi: 10.1097/CEJ.0b013e328355ec22.

PMID:
22694828
15.

Full Field Digital Mammography (FFDM) versus CMOS Technology versus Tomosynthesis (DBT) - Which System Increases the Quality of Intraoperative Imaging?

Schulz-Wendtland R, Dilbat G, Bani M, Fasching PA, Lux MP, Wenkel E, Schwab S, Loehberg CR, Jud SM, Rauh C, Bayer CM, Beckmann MW, Uder M, Meier-Meitinger M.

Geburtshilfe Frauenheilkd. 2012 Jun;72(6):532-538.

16.

Pilot Study on the Detection of Simulated Lesions Using a 2D and 3D Digital Full-Field Mammography System with a Newly Developed High Resolution Detector Based on Two Shifts of a-Se.

Schulz-Wendtland R, Bani M, Lux MP, Schwab S, Loehberg CR, Jud SM, Rauh C, Bayer CM, Beckmann MW, Uder M, Fasching PA, Adamietz B, Meier-Meitinger M.

Geburtshilfe Frauenheilkd. 2012 May;72(5):408-411.

17.

Characterizing mammographic images by using generic texture features.

Häberle L, Wagner F, Fasching PA, Jud SM, Heusinger K, Loehberg CR, Hein A, Bayer CM, Hack CC, Lux MP, Binder K, Elter M, Münzenmayer C, Schulz-Wendtland R, Meier-Meitinger M, Adamietz BR, Uder M, Beckmann MW, Wittenberg T.

Breast Cancer Res. 2012 Apr 10;14(2):R59.

18.

Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection.

Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, Bayer CM, Bani MR, Richter S, Adamietz BR, Wenkel E, Rauh C, Beckmann MW, Fasching PA.

PLoS One. 2012;7(1):e29770. doi: 10.1371/journal.pone.0029770.

19.

Breast Cancer Risk - Genes, Environment and Clinics.

Fasching PA, Ekici AB, Adamietz BR, Wachter DL, Hein A, Bayer CM, Häberle L, Loehberg CR, Jud SM, Heusinger K, Rübner M, Rauh C, Bani MR, Lux MP, Schulz-Wendtland R, Hartmann A, Beckmann MW.

Geburtshilfe Frauenheilkd. 2011 Dec;71(12):1056-1066.

20.

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.

Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL.

BMC Cancer. 2011 Nov 14;11:486. doi: 10.1186/1471-2407-11-486.

Items per page

Supplemental Content

Loading ...
Support Center